Finance Watch: Another VC Mega-Round As Flare Raises $123m Series B
Lead Program Moves Into Clinic Two Years After Series A
Executive Summary
Private Company Edition: Flare Therapeutics, targeting transcription factors to discover precision medicines, had big pharma backing for its second venture capital financing. Also, Mediar closed a $10m series A round, Switch launched with $52m and EpiBiologics raised a $50m series A round.
You may also be interested in...
Finance Watch: Dementia Discovery Fund’s Behr Sees Early Investments Reviving Neuroscience Interest
Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each.
Finance Watch: Four Biotech VC Funds Raise $1.7bn Combined
Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline.
Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.